Table Info

Table 1.

Activity of MZ1, birabresib and cisMZ1 in ABC DLBCL cell lines

Cell line	MZ1 (nmol/L)		Birabresib (nmol/L)		CisMZ1 (nmol/L)
Cell line	IC₅₀	AUC	IC₅₀	AUC	IC₅₀	AUC
HBL1	61.68	17,036	292.38	43,057	> 2,000	89,050
OCI-LY-10	4.39	1,302	125.91	33,067	> 2,000	94,936
OCI-LY-3	22.76	3,934	98.35	26,973	> 2,000	89,072
RI-1	134.88	32,997	394.42	50,586	> 2,000	86,715
SU-DHL-2	48.95	14,789	68.42	17,690	> 2,000	88,269
TMD8	39.10	6,847	106.92	19,826	> 2,000	99,547
U2932	109.03	24,749	470.57	53,025	> 2,000	96,221

Median IC₅₀	48.95		125.91		n.a.
95% CI	10.16–126.76		77.83–446.64		n.a.

Median AUC		14,789		33,067		89,072
95% CI		1,302–32,997		17,690–53,025		86,715–99,547

Seven ABC DLBCL lymphoma cell lines were exposed to increasing concentrations of MZ1, birabresib or cisMZ1 for 72 h. Table shows the IC₅₀ and AUC values for each cell line, 95% CI of median IC₅₀ and AUC for each drug. n.a.: not avalable

Supplementary materials

The supplementary Figures for this article are available at: https://www.explorationpub.com/uploads/Article/file/100265_sup_1.pdf. The supplementary Tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/100265_sup_2.xlsx.

Declarations

Acknowledgments

The authors would like to thank the Colleagues at BigOmics Analytics SA (Viganello, Switzerland) for their support in using their on-line tool.

Author contributions

Conception and design: CT, AC, FB. Development of methodology: CT, EG, AT, CM, AC, FB. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): CT, LC, FB. Writing, review, and/or revision of the manuscript: CT, EZ, AS, AC, FB. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): CT, FB. Study supervision: FB. Others (performed experiments): CT, HE, CM, EG, EC, CR, SN, AR. All authors have approved the submitted version and have agreed to both be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated.

Conflicts of interest

EZ: institutional research funds from Celgene, Roche, and Janssen; advisory board fees from Celgene, Roche, Mei Pharma, Astra Zeneca, and Celltrion Healthcare; travel grants from Abbvie and Gilead; expert statements provided to Gilead, Bristol-Myers Squibb, and MSD. AS: institutional research funds from: Bayer, Merck, Pfizer, Novartis, Roche, MEI Pharma, ADC-Therapeutics; travel grant from AbbVie and PharmaMar. AC: scientific founder, director, consultant and shareholder of Amphista Therapeutics; institutional research funds from Amphista therapeutics, Boehringer Ingelheim, Eisai, and Nurix, Inc. and One Pharma. FB: institutional research funds from Acerta, ADC Therapeutics, Bayer AG, Cellestia, CTI Life Sciences, EMD Serono, Helsinn, ImmunoGen, Menarini Ricerche, NEOMED Therapeutics 1, Nordic Nanovector ASA, Oncology Therapeutic Development, PIQUR Therapeutics AG; consultancy fee from Helsinn, Menarini; expert statements provided to HTG; travel grants from Amgen, Astra Zeneca, Jazz Pharmaceuticals, PIQUR Therapeutics AG. The other authors have nothing to disclose.

Ethical approval

Mice maintenance and animal experiments were performed under the institutional guidelines established for the Animal Facility and with study protocols approved by the local Cantonal Veterinary Authority (license TI-23/2015).

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

All transcriptome data are available at GEO (http://www.ncbi.nlm.nih.gov/geo).

Funding

Not applicable.

Copyright

References

Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298–310. [DOI] [PubMed]

Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018;131:2307–19. [DOI] [PubMed] [PMC]

Miao Y, Medeiros LJ, Li Y, Li J, Young KH. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16:634–52. [DOI] [PubMed]

Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551–68.e14. [DOI] [PubMed] [PMC]

Cascione L, Aresu L, Baudis M, Bertoni F. DNA copy number changes in diffuse large B cell lymphomas. Front Oncol. 2020;10:584095. [DOI] [PubMed] [PMC]

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–90. [DOI] [PubMed] [PMC]

Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, et al. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A. 2014;111:11365–70. [DOI] [PubMed] [PMC]

Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24:777–90. [DOI] [PubMed] [PMC]

Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res. 2015;21:1628–38. [DOI] [PubMed]

10.

Bernasconi E, Gaudio E, Lejeune P, Tarantelli C, Cascione L, Kwee I, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017;178:936–48. [DOI] [PubMed]

11.

Blum KA, Abramson J, Maris M, Flinn I, Goy A, Mertz J, et al. A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma. Ann Oncol. 2018;29:iii7–9. [DOI]

12.

Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3:e196–204. [DOI] [PubMed]

13.

Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018;8:24–36. [DOI] [PubMed]

14.

Donati B, Lorenzini E, Ciarrocchi A. BRD4 and cancer: going beyond transcriptional regulation. Mol Cancer.2018;17:164. [DOI] [PubMed] [PMC]

15.

Spriano F, Stathis A, Bertoni F. Targeting BET bromodomain proteins in cancer: the example of lymphomas. Pharmacol Ther. 2020;215:107631. [DOI] [PubMed]

16.

Lambert JP, Picaud S, Fujisawa T, Hou H, Savitsky P, Uusküla-Reimand L, et al. Interactome rewiring following pharmacological targeting of BET bromodomains. Mol Cell. 2019;73:621–38.e17. [DOI] [PubMed] [PMC]

17.

Andrieu GP, Denis GV. BET proteins exhibit transcriptional and functional opposition in the epithelial-to-mesenchymal transition. Mol Cancer Res. 2018;16:580–6. [DOI] [PubMed] [PMC]

18.

Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer. 2012;12:465–77. [DOI] [PubMed] [PMC]

19.

Deeney JT, Belkina AC, Shirihai OS, Corkey BE, Denis GV. BET bromodomain proteins Brd2, Brd3 and Brd4 selectively regulate metabolic pathways in the pancreatic β-cell. PLoS One. 2016;11:e0151329. [DOI] [PubMed] [PMC]

20.

Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13:337–56. [DOI] [PubMed]

21.

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–17. [DOI] [PubMed] [PMC]

22.

Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560:387–91. [DOI] [PubMed] [PMC]

23.

Zou Z, Huang B, Wu X, Zhang H, Qi J, Bradner J, et al. Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene. 2014;33:2395–404. [DOI] [PubMed] [PMC]

24.

Greenwald RJ, Tumang JR, Sinha A, Currier N, Cardiff RD, Rothstein TL, et al. E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood. 2004;103:1475–84. [DOI] [PubMed] [PMC]

25.

Belkina AC, Blanton WP, Nikolajczyk BS, Denis GV. The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis. J Leukoc Biol. 2014;95:451–60. [DOI] [PubMed] [PMC]

26.

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016;3:e186–95. [DOI] [PubMed]

27.

Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, et al. Phase Ib trial with birabresib, a small- molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol. 2018;36:3007–14. [DOI] [PubMed]

28.

Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, et al. First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors. Clin Cancer Res. 2019;25:6309–19. [DOI] [PubMed]

29.

Postel-Vinay S, Herbschleb K, Massard C, Woodcock V, Soria JC, Walter AO, et al. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/ pharmacodynamic relationship and early termination due to unexpected toxicity. Eur J Cancer. 2019;109:103–10. [DOI] [PubMed]

30.

Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, et al. Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies. Clin Cancer Res. 2020;26:1247–57. [DOI] [PubMed] [PMC]

31.

Moreno V, Sepulveda JM, Vieito M, Hernández-Guerrero T, Doger B, Saavedra O, et al. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/ refractory non-Hodgkin’s lymphoma. Ann Oncol. 2020;31:780–8. [DOI] [PubMed]

32.

Piha-Paul SA, Hann CL, French CA, Cousin S, Braña I, Cassier PA, et al. Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors. JNCI Cancer Spectr. 2019;4:pkz093. [DOI] [PubMed] [PMC]

33.

Shapiro GI, LoRusso P, Dowlati A, T Do K, Jacobson CA, Vaishampayan U, et al. A phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021;124:744–53. [DOI] [PubMed] [PMC]

34.

Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res. 2013;19:6183–92. [DOI] [PubMed] [PMC]

35.

Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol. 2015;22:755–63. [DOI] [PubMed] [PMC]

36.

Astorgues-Xerri L, Vázquez R, Odore E, Rezai K, Kahatt C, Mackenzie S, et al. Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models. Leuk Lymphoma. 2019;60:3067–70. [DOI] [PubMed]

37.

Vázquez R, Riveiro ME, Astorgues-Xerri L, Odore E, Rezai K, Erba E, et al. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget. 2017;8:7598–613. [DOI] [PubMed] [PMC]

38.

Raina K, Crews CM. Chemical inducers of targeted protein degradation. J Biol Chem. 2010;285:11057–60. [DOI] [PubMed] [PMC]

39.

Dale B, Cheng M, Park KS, Kaniskan HÜ, Xiong Y, Jin J. Advancing targeted protein degradation for cancer therapy. Nat Rev Cancer. 2021;21:638–54. [DOI] [PubMed]

40.

Troup RI, Fallan C, Baud MGJ. Current strategies for the design of PROTAC linkers: a critical review. Explor Target Antitumor Ther. 2020;1:273–312. [DOI]

41.

Duan Y, Guan Y, Qin W, Zhai X, Yu B, Liu H. Targeting Brd4 for cancer therapy: inhibitors and degraders. Medchemcomm. 2018;9:1779–802. [DOI] [PubMed] [PMC]

42.

Zengerle M, Chan KH, Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem Biol. 2015;10:1770–7. [DOI] [PubMed] [PMC]

43.

Gaudio E, Tarantelli C, Spriano F, Guidetti F, Sartori G, Bordone R, et al. Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. Haematologica. 2020;105:2584–91. [DOI] [PubMed] [PMC]

44.

Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, et al. PQR309 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy. Clin Cancer Res. 2018;24:120–9. [DOI] [PubMed]

45.

Aresu L, Ferraresso S, Marconato L, Cascione L, Napoli S, Gaudio E, et al. New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. Haematologica. 2019;104:e256–9. [DOI] [PubMed] [PMC]

46.

Ullman-Culleré MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999;49:319–23. [PubMed]

47.

Spriano F, Chung EYL, Gaudio E, Tarantelli C, Cascione L, Napoli S, et al. The ETS inhibitors YK-4-279 and TK-216 are novel antilymphoma agents. Clin Cancer Res. 2019;25:5167–76. [DOI] [PubMed]

48.

Cascione L, Rinaldi A, Bruscaggin A, Tarantelli C, Arribas AJ, Kwee I, et al. Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. Haematologica. 2019;104:e558–61. [DOI] [PubMed] [PMC]

49.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50. [DOI] [PubMed] [PMC]

50.

Shaffer AL, Wright G, Yang L, Powell J, Ngo V, Lamy L, et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev. 2006;210:67–85. [DOI] [PubMed]

51.

Akhmedov M, Martinelli A, Geiger R, Kwee I. Omics playground: a comprehensive self-service platform for visualization, analytics and exploration of Big Omics Data. NAR Genom Bioinform. 2019;2:lqz019. [DOI] [PubMed] [PMC]

52.

Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171:1437–52.e17. [DOI] [PubMed] [PMC]

53.

Spriano F, Gaudio E, Cascione L, Tarantelli C, Melle F, Motta G, et al. Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood Adv. 2020;4:4124–35. [DOI] [PubMed] [PMC]

54.

Yeh TC, O’Connor G, Petteruti P, Dulak A, Hattersley M, Barrett JC, et al. Identification of CCR2 and CD180 as robust pharmacodynamic tumor and blood biomarkers for clinical use with BRD4/BET inhibitors. Clin Cancer Res. 2017;23:1025–35. [DOI] [PubMed]

55.

Lin X, Huang X, Uziel T, Hessler P, Albert DH, Roberts-Rapp LA, et al. HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues. Mol Cancer Ther. 2017;16:388–96. [DOI] [PubMed]

56.

Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011;108:16669–74. [DOI] [PubMed] [PMC]

57.

Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120:2843–52. [DOI] [PubMed] [PMC]

58.

Berenguer-Daizé C, Astorgues-Xerri L, Odore E, Cayol M, Cvitkovic E, Noel K, et al. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. Int J Cancer. 2016;139:2047–55. [DOI] [PubMed]

59.

Riveiro ME, Kwee I, Astorgues-Xerri L, Bekradda M, Vazquez R, Rinaldi A, et al. Abstract 3530: gene expression profile of OTX015, a BET bromodomain inhibitor, in preclinical models of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) models. Cancer Res. 2015;75:3530. [DOI]

60.

Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, et al. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci Transl Med. 2019;11:eaav5599. [DOI] [PubMed] [PMC]

61.

Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, et al. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. 2018;32:343–52. [DOI] [PubMed]

62.

Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AM, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016;113:7124–9. [DOI] [PubMed] [PMC]

63.

Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140:3079–93. [DOI] [PubMed]

64.

Winter GE, Mayer A, Buckley DL, Erb MA, Roderick JE, Vittori S, et al. BET bromodomain proteins function as master transcription elongation factors independent of CDK9 pecruitment. Mol Cell. 2017;67:5–18.e19. [DOI] [PubMed] [PMC]

65.

Pizzi M, Boi M, Bertoni F, Inghirami G. Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. Leukemia. 2016;30:1805–15. [DOI] [PubMed]

66.

Aspeslagh S, Morel D, Soria JC, Postel-Vinay S. Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Ann Oncol. 2018;29:812–24. [DOI] [PubMed]

67.

Jensen SM, Potts GK, Ready DB, Patterson MJ. Specific MHC-I peptides are induced using PROTACs. Front Immunol. 2018;9:2697. [DOI] [PubMed] [PMC]

68.

Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 2003;63:5505–12. [PubMed]

69.

Yang X, Lu P, Fujii C, Nakamoto Y, Gao JL, Kaneko S, et al. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int J Cancer. 2006;118:1869–76. [DOI] [PubMed]

70.

Luo X, Yu Y, Liang A, Xie Y, Liu S, Guo J, et al. Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells. Cell Mol Immunol. 2004;1:199–204. [PubMed]

71.

Zibert A, Balzer S, Souquet M, Quang TH, Paris-Scholz C, Roskrow M, et al. CCL3/MIP-1alpha is a potent immunostimulator when coexpressed with interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine. Hum Gene Ther. 2004;15:21–34. [DOI] [PubMed]

72.

Allen F, Rauhe P, Askew D, Tong AA, Nthale J, Eid S, et al. CCL3 enhances antitumor immune priming in the lymph node via IFNγ with dependency on natural killer cells. Front Immunol. 2017;8:1390. [DOI] [PubMed] [PMC]

73.

Cittera E, Leidi M, Buracchi C, Pasqualini F, Sozzani S, Vecchi A, et al. The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol. 2007;178:6616–23. [DOI] [PubMed]

74.

Zucchetto A, Tripodo C, Benedetti D, Deaglio S, Gaidano G, Del Poeta G, et al. Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38⁺CD49d⁺ chronic lymphocytic leukaemia cells. Br J Haematol. 2010;150:111–3. [DOI] [PubMed]

75.

Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, et al. CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011;117:1662–9. [DOI] [PubMed] [PMC]

76.

Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, et al. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015;171:726–35. [DOI] [PubMed] [PMC]

77.

Tinsley S, Meja K, Shepherd C, Khwaja A. Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition. Br J Haematol. 2015;170:275–8. [DOI] [PubMed]

78.

Stubbs M, Maduskuie T, Burn T, Diamond-Fosbenner S, Falahatpisheh N, Volgina A, et al. Abstract 5071: preclinical characterization of the potent and selective BET inhibitor INCB057643 in models of hematologic malignancies. Cancer Res. 2017;77:5071. [DOI]

79.

Meadows S, Yahiaoui A, Sorensen R, Cui ZH, Brockett R, Keegan KS, et al. Evaluation of idelalisib with B-cell receptor or orthogonal pathway inhibitors in diffuse large B-Cell lymphoma cell lines in vitro and in vivo. Blood. 2016;128:1845. [DOI]

80.

Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, et al. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2020;34:1588–98. [DOI] [PubMed] [PMC]

81.

Derenzini E, Mondello P, Erazo T, Portelinha A, Liu Y, Scallion M, et al. BET inhibition-induced GSK3β feedback enhances lymphoma vulnerability to PI3K inhibitors. Cell Rep. 2018;24:2155–66. [DOI] [PubMed] [PMC]

82.

Otto C, Schmidt S, Kastner C, Denk S, Kettler J, Müller N, et al. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells. Neoplasia. 2019;21:1110–20. [DOI] [PubMed] [PMC]

83.

Noblejas-López MDM, Nieto-Jimenez C, Burgos M, Gómez-Juárez M, Montero JC, Esparís-Ogando A, et al. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. J Exp Clin Cancer Res. 2019;38:383. [DOI] [PubMed] [PMC]

84.

Shafran JS, Andrieu GP, Györffy B, Denis GV. BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK. Mol Cancer Res. 2019;17:1627–38. [DOI] [PubMed] [PMC]

85.

Chan KH, Zengerle M, Testa A, Ciulli A. Impact of target warhead and linkage vector on inducing protein degradation: comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds. J Med Chem. 2018;61:504–13. [DOI] [PubMed] [PMC]